Chronic Lymphocytic Leukaemia
Chronic lymphocytic leukaemia (CLL) is a cancer of the B-lymphocytes, white blood cells that normally fight infection. Abnormal cells accumulate in the blood, bone marrow, and lymph nodes rather than dying at the end of their natural cycle. CLL tends to progress slowly, and many people live with it for years before it requires treatment.
Key points
- Abnormal white blood cells accumulate instead of dying off naturally, and many people live for years before treatment becomes necessary.
- Routine blood tests often reveal the condition before any symptoms such as fatigue or swollen lymph nodes appear.
- Not every diagnosis needs immediate treatment, since staging systems and biological markers help doctors judge the likely pace of disease.
- Chlorambucil, an older alkylating agent, remains a go-to choice for elderly or frailer patients who cannot manage harsher treatment regimens.
How CLL behaves and when treatment begins
Many cases are picked up incidentally on a routine blood test before any symptoms appear. When symptoms do develop they typically include persistent fatigue, swollen lymph nodes in the neck or armpits, night sweats, and a tendency to catch infections more easily. Some people experience an enlarged spleen causing discomfort under the left ribs.
Not every diagnosis calls for immediate treatment. Doctors use staging systems and specific biological markers to judge pace and risk. When treatment is needed, chlorambucil, a long-established alkylating agent, has been a standard option for older or less-fit patients who may not tolerate more intensive regimens. It sits within the broader oncology support range. Regular monitoring of blood counts remains central to management throughout the disease course.